Exagen Inc. to Participate in Upcoming March Conferences
February 27, 2023 09:00 ET
|
Exagen Inc.
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March...
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
October 31, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022,...
Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
September 01, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory...
Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 25, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42nd Annual...
Exagen Inc. Expands Coverage with MediNcrease
June 09, 2022 08:25 ET
|
Exagen Inc.
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans,...
Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
May 26, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 42nd Annual Growth...
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
May 16, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered...
Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference
April 20, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2...
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
March 16, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB)...